Bristol Myers Squibb lung fibrosis drug meets Phase 3 trial goal

October 12, 2026 6:50 AM

Bristol Myers Squibb (NYSE: BMY) announced that its Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary fibrosis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found